参考文献: https://www.mskcc.org/news/potential-new-treatment-for-kras-gi2d-lung-cancer-reported-in-first-of-its-kind-clinical-trial https://www.onclive.com/view/zoldonrasib-shows-encouraging-early-antitumor-activity-in-kras-g12d-mutated-nsclc https://ascopubs.org/doi/pdf/10.1200/JCO.2025.43...
2. https://www.targetedonc.com/view/rmc-9805-hits-milestone-in-early-phase-clinical-trial-of-kras-g12d-solid-tumors
RMC-9805 was proven safe and active in patients with previously treated, KRAS G12D–mutant pancreatic ductal adenocarcinoma (PDAC), according to preliminary data from the phase 1/1b RMC-9805-001 trial (NCT06040541) that were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the first patient was dosed in its Phase 1/1b monotherapy clinical trial of R...
请在备注中输入口令:09274 参考来源: https://www.targetedonc.com/view/rmc-9805-hits-milestone-in-early-phase-clinical-trial-of-kras-g12d-solid-tumors
https://www./news/potential-new-treatment-for-kras-gi2d-lung-cancer-reported-in-first-of-its-kind-clinical-trial https://www./view/zoldonrasib-shows-encouraging-early-antitumor-activity-in-kras-g12d-mutated-nsclc https:///doi/pdf/10.1200/JCO.2025.43.4_suppl.724...